Navigation Links
Pressure BioSciences, Inc. to Discuss First Quarter 2013 Financial Results and Provide Business Update
Date:5/23/2013

SOUTH EASTON, Mass., May 23, 2013 /PRNewswire/ -- Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" and the "Company") today announced that the Company will host a teleconference to discuss its First Quarter 2013 financial results and to provide a business update. The teleconference information is provided below:

Date: Thursday, May 23, 2013
Time: 11:00 a.m. Eastern Daylight Time (EDT)

Dial-in: (800) 875-3456 (U.S.); (800) 648-0973 (Canada); (302) 607-2001 (Int'l)
Passcode: VS22823

For those unable to participate in the live teleconference, a replay will be available approximately one hour after the call and will be accessible through the Company's website.

About Pressure BioSciences, Inc.

Pressure BioSciences, Inc. ("PBI") (OTCQB: PBIO) is focused on the development, marketing, and sale of proprietary laboratory instrumentation and associated consumables based on Pressure Cycling Technology ("PCT"). PCT is a patented, enabling technology platform with multiple applications in the estimated $6 billion life sciences sample preparation market. PCT uses cycles of hydrostatic pressure between ambient and ultra-high levels to control bio-molecular interactions. PBI currently focuses its efforts on the development and sale of PCT-enhanced sample preparation systems (instruments and consumables) for mass spectrometry, biomarker discovery, bio-therapeutics characterization, vaccine development, soil and plant biology, forensics, histology, and counter-bioterror applications.

For more information about PBI and this press release, please click on the following link:
http://www.pressurebiosciences.com




Investor Contacts:

Richard T. Schumacher, President & CEO

Pressure BioSciences, Inc.

Conrad Mir, CFO

(T) 508-230-1828


'/>"/>
SOURCE Pressure BioSciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. High pressure gold nanocrystal structure revealed
2. Further Advancements Made in the Development of an Improved Method For Rape Kit Testing Using Pressure BioSciences Patented Pressure Cycling Technology (PCT)
3. New Applications of Pressure BioSciences PCT Platform Prominently Featured at Scientific Conference on Technologies for Protein Research
4. Pressure BioSciences, Inc. Appoints Conrad F. Mir as Chief Financial Officer
5. Pressure BioSciences, Inc. Continues Global Sales Reach Expansion with Distribution Agreements for China, Vietnam, Laos, Cambodia, Australia, and New Zealand
6. Pressure BioSciences, Inc. Reaches Agreement with Investors on Initial $600,000 Tranche of $1.2 Million Above-Market Private Placement; Proceeds to Support Continued Commercialization of PCT Product Platform
7. Regado Biosciences, Inc. Files Registration Statement for Proposed Initial Public Offering
8. Regado Biosciences, Inc. to Present at Needham & Companys 11th Annual Healthcare Conference in New York, NY
9. Shire to Acquire FerroKin BioSciences, Inc., and its Phase 2 Iron Chelator Treatment
10. Regado Biosciences, Inc. to Present at the Cowen and Company 32nd Annual Health Care Conference in Boston, MA
11. The 2013 Bioprocessing Summit to Bring Together International Leaders to Discuss Today's Bioprocess Issues From Cell Line Selection to Manufacturing in Boston, MA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... , March 23, 2017  SeraCare Life ... global in vitro diagnostics manufacturers and clinical ... industry,s first multiplexed Inherited Cancer reference ... by next-generation sequencing (NGS). The Seraseq™ Inherited ... with input from industry experts to validate ...
(Date:3/23/2017)... YORK , March 23, 2017 ... ... of death, putting significant strain on health care systems, in ... cancer diagnoses rises, so too does the development of innovative ... minimum side effects. Among the many types of cancer treatments, ...
(Date:3/22/2017)... March 22, 2017 Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), ... Center (RGC), U.K. Biobank and GSK to generate genetic sequence ... resource. The initiative will enable researchers to gain valuable insights ... a wide range of serious and life threatening diseases. ... Genetic evidence ...
(Date:3/22/2017)... -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP ... ), a clinical-stage pharmaceutical company focused on the ... that Dr. Miriam Kidron , Oramed,s Chief ... Insulin for Diabetes Treatment: Bypassing the Roadblock," at ... Therapeutics (OPT) Boston Conference in Cambridge, Massachusetts ...
Breaking Biology Technology:
(Date:2/28/2017)...  EyeLock LLC, ein marktführendes Unternehmen im Bereich ... Lösung zur Iris-Erkennung auf der neuesten Mobilplattform ... dem Mobile World Congress 2017 (27. Februar ... 3, Stand 3E10, vorstellen. Der ... – eine Kombination aus Hardware, Software und ...
(Date:2/24/2017)... , Feb. 24, 2017  EyeLock LLC, a leader of ... elite iris biometric solution on the latest Qualcomm® ... at Mobile World Congress 2017 (February 27 ... in Hall 3, Stand 3E10. ... Haven™ security platform—a combination of hardware, software ...
(Date:2/21/2017)... Der weltweite Biobanking-Sektor wird bis ... Gespräch mit mehr als 50 Vertretern aus verschiedenen Branchen wurde ... um diese Prognose zu realisieren. ... Zu den Schwierigkeiten ... Mittel für die Biobank, die Implementierung Zeit sparender Technologien, ...
Breaking Biology News(10 mins):